Analyst Coverage

Adial Pharmaceutical, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Adial Pharmaceutical, Inc.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Adial Pharmaceutical, Inc. or its management. Adial Pharmaceutical, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) is a biopharmaceutical company. Following its acquisition of Azora Therapeutics, Adial’s pipeline now includes AT177, a novel, colon-targeted aryl hydrocarbon receptor (AhR) agonist in development for ulcerative colitis, as well as AD04, a genetically targeted serotonin-3 receptor antagonist being advanced through a new Phase 3 clinical trial program for the treatment of Alcohol Use Disorder in patients with certain target genotypes.